Phaseline

Companies › Werewolf Therapeutics

Werewolf Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WTX-330
Bispecific antibody engaging immune effector cells
–Phase 1Advanced or Metastatic Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06939283WTX-330Phase 1Advanced or Metastatic Solid TumorsOncologyApr 2026

From the company's SEC filings

Cash of $22m on 2026-06-30; operating cash outflow about $8m a year; runway about 33 months at that burn, to Mar 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.